229 related articles for article (PubMed ID: 9212478)
61. Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study.
Mercadante S; Aielli F; Adile C; Costanzi A; Casuccio A
J Pain Symptom Manage; 2016 Jul; 52(1):27-34. PubMed ID: 27208863
[TBL] [Abstract][Full Text] [Related]
62. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
[TBL] [Abstract][Full Text] [Related]
63. The effectiveness of subcutaneously implanted epidural ports for relief of severe pain in patients with advanced-stage gynecological cancer: a prospective study.
Ertaş IE; Sehirali S; Ozsezgin Ocek S; Sancı M; Arbak G; Yıldırım Y
Agri; 2014; 26(1):8-14. PubMed ID: 24481578
[TBL] [Abstract][Full Text] [Related]
64. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Lauretti GR; Lima IC; Reis MP; Prado WA; Pereira NL
Anesthesiology; 1999 Jun; 90(6):1528-33. PubMed ID: 10360847
[TBL] [Abstract][Full Text] [Related]
65. The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients.
Reddy A; Tayjasanant S; Haider A; Heung Y; Wu J; Liu D; Yennurajalingam S; Reddy S; de la Cruz M; Rodriguez EM; Waletich J; Vidal M; Arthur J; Holmes C; Tallie K; Wong A; Dev R; Williams J; Bruera E
Cancer; 2016 Jan; 122(1):149-56. PubMed ID: 26451687
[TBL] [Abstract][Full Text] [Related]
66. The Opioid Rotation Ratio From Transdermal Fentanyl to "Strong" Opioids in Patients With Cancer Pain.
Reddy A; Yennurajalingam S; Reddy S; Wu J; Liu D; Dev R; Bruera E
J Pain Symptom Manage; 2016 Jun; 51(6):1040-5. PubMed ID: 26826675
[TBL] [Abstract][Full Text] [Related]
67. Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis.
Yang Q; Xie DR; Jiang ZM; Ma W; Zhang YD; Bi ZF; Chen DL
J Exp Clin Cancer Res; 2010 Jun; 29(1):67. PubMed ID: 20529380
[TBL] [Abstract][Full Text] [Related]
68. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH
Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476
[TBL] [Abstract][Full Text] [Related]
69. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany.
Sittl R; Nuijten M; Poulsen Nautrup B
Clin Ther; 2006 Aug; 28(8):1144-1154. PubMed ID: 16982291
[TBL] [Abstract][Full Text] [Related]
70. Intravenous morphine for rapid control of severe cancer pain.
Harris JT; Suresh Kumar K; Rajagopal MR
Palliat Med; 2003 Apr; 17(3):248-56. PubMed ID: 12725478
[TBL] [Abstract][Full Text] [Related]
71. [Dose-finding for treatment with a transdermal fentanyl patch : Titration with oral transmucosal fentanyl citrate and morphine sulfate].
Mücke M; Conrad R; Marinova M; Cuhls H; Elsner F; Rolke R; Radbruch L
Schmerz; 2016 Dec; 30(6):560-567. PubMed ID: 27072143
[TBL] [Abstract][Full Text] [Related]
72. Assessment of analgesia in human chronic pain. Randomized double-blind crossover study of once daily repro-dose morphine versus MST continus.
Peat S; Sweet P; Miah Y; Barklamb M; Larsen U
Eur J Clin Pharmacol; 1999 Oct; 55(8):577-81. PubMed ID: 10541775
[TBL] [Abstract][Full Text] [Related]
73. [The cognitive effects of using transdermal fentanyl in cancer pain].
Unlü N; Bilen A; Ali A; Turgut N; Türkmen A
Agri; 2014; 26(3):126-30. PubMed ID: 25205411
[TBL] [Abstract][Full Text] [Related]
74. Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line.
Hoya Y; Okamoto T; Yanaga K
Support Care Cancer; 2010 Jun; 18(6):761-4. PubMed ID: 20354734
[TBL] [Abstract][Full Text] [Related]
75. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region.
Grond S; Zech D; Lehmann KA; Radbruch L; Breitenbach H; Hertel D
Pain; 1997 Jan; 69(1-2):191-8. PubMed ID: 9060030
[TBL] [Abstract][Full Text] [Related]
76. Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care.
McNamara P
Palliat Med; 2002 Sep; 16(5):425-34. PubMed ID: 12380661
[TBL] [Abstract][Full Text] [Related]
77. Treatment of severe cancer pain by transdermal fentanyl.
Ljuca D; Husić S
Bosn J Basic Med Sci; 2010 May; 10(2):158-64. PubMed ID: 20507298
[TBL] [Abstract][Full Text] [Related]
78. [Use of Transdermal Fentanyl in a Hospital].
Sako A; Yoshikawa Y; Kikuchi N; Watanabe A; Yoshida S
Gan To Kagaku Ryoho; 2016 Mar; 43(3):341-4. PubMed ID: 27067851
[TBL] [Abstract][Full Text] [Related]
79. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients.
Portenoy RK; Raffaeli W; Torres LM; Sitte T; Deka AC; Herrera IG; Wallace MS;
J Opioid Manag; 2010; 6(5):319-28. PubMed ID: 21046929
[TBL] [Abstract][Full Text] [Related]
80. Efficacy and safety of transdermal fentanyl for the treatment of oral mucositis pain caused by chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Xing SZ; Zhang Y
Support Care Cancer; 2015 Mar; 23(3):753-9. PubMed ID: 25179692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
